How much funding has Scribe Therapeutics raised?

Scribe Therapeutics has raised $100.0M in total funding, most recently a Series B round.

Who are Scribe Therapeutics's investors?

Scribe Therapeutics's investors include Avoro Ventures, OrbiMed, Andreessen Horowitz.

When was Scribe Therapeutics founded?

Scribe Therapeutics was founded in 2018.

Where is Scribe Therapeutics headquartered?

Scribe Therapeutics is headquartered in Alameda, California, United States.

What industry is Scribe Therapeutics in?

Scribe Therapeutics operates in Healthcare.

How many employees does Scribe Therapeutics have?

Scribe Therapeutics has 51-200 employees.

Scribe Therapeutics

Rewriting medicine with molecular engineering

Alameda, United States · Founded 2018 · $100.0M raised

Healthcare

Headquarters: Alameda, California
Employees: 51–200
Founded: 2018
Business Model: B2B

Website: scribetx.com
Total Funding: $100.0M
Last Round: $100.0M Series BMar 2021
Rounds: 1

About

Scribe Therapeutics is a molecular engineering company developing best-in-class CRISPR-based genetic medicines, founded by Nobel Prize-winning CRISPR pioneer Jennifer Doudna and colleagues at UC Berkeley. The company engineers optimized in vivo CRISPR systems targeting cardiometabolic diseases, with partnerships with Eli Lilly and Sanofi and programs projected to enter the clinic in mid-2026.

Summary

Scribe Therapeutics is a Healthcare company based in Alameda, United States, founded in 2018. It has raised $100.0M in total across 1 round, most recently a $100.0M Series B round in Mar 2021. Investors include Avoro Ventures, OrbiMed and Andreessen Horowitz.

LinkedIn X (Twitter)